Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies
Pegylated liposomal doxorubicin (PLD) is a palliative treatment option for patients with recurrent gynecologic malignancies. It has an appealing toxicity profile and responses can be prolonged. There is no consensus as to the level of cardiac toxicity. Current label warnings, National Comprehensive...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Book |
| Published: |
Elsevier,
2019-08-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
| LEADER | 00000 am a22000003u 4500 | ||
|---|---|---|---|
| 001 | doaj_2e9d44a8f6ee46bd9bc79b14fb976632 | ||
| 042 | |a dc | ||
| 100 | 1 | 0 | |a S. Yost |e author |
| 700 | 1 | 0 | |a J.L. Konal |e author |
| 700 | 1 | 0 | |a A.V. Hoekstra |e author |
| 245 | 0 | 0 | |a Prolonged use of pegylated liposomal doxorubicin in gynecologic malignancies |
| 260 | |b Elsevier, |c 2019-08-01T00:00:00Z. | ||
| 500 | |a 2352-5789 | ||
| 500 | |a 10.1016/j.gore.2019.07.012 | ||
| 520 | |a Pegylated liposomal doxorubicin (PLD) is a palliative treatment option for patients with recurrent gynecologic malignancies. It has an appealing toxicity profile and responses can be prolonged. There is no consensus as to the level of cardiac toxicity. Current label warnings, National Comprehensive Cancer Network (NCCN) guidelines, and extrapolation of prescribing guidelines from doxorubicin, may limit PLD's use in patients with baseline cardiac comorbidities, limit the lifetime dosing of an effective palliative treatment, or lead to over-use of unnecessary cardiac testing. This case series describes the experience of 18 patients using prolonged courses of PLD for gynecologic malignancies with no cardiac toxicity. Keywords: Pegylated liposomal doxorubicin, Cardiac toxicity, Palliative, Prolonged | ||
| 546 | |a EN | ||
| 690 | |a Gynecology and obstetrics | ||
| 690 | |a RG1-991 | ||
| 690 | |a Neoplasms. Tumors. Oncology. Including cancer and carcinogens | ||
| 690 | |a RC254-282 | ||
| 655 | 7 | |a article |2 local | |
| 786 | 0 | |n Gynecologic Oncology Reports, Vol 29, Iss , Pp 89-93 (2019) | |
| 787 | 0 | |n http://www.sciencedirect.com/science/article/pii/S2352578919300748 | |
| 787 | 0 | |n https://doaj.org/toc/2352-5789 | |
| 856 | 4 | 1 | |u https://doaj.org/article/2e9d44a8f6ee46bd9bc79b14fb976632 |z Connect to this object online. |